The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Are we ready for triplet therapy in MDS?
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, briefly discusses the current treatment landscape in myelodysplastic syndromes (MDS), where a great deal of progress has been made in improving on the old standard of care. Although Dr Brunner hopes that the use of triplet regimens for the treatment of patients with MDS is on the horizon, he believes that a significant amount of investigation into possible therapy approaches is required and that the heterogeneity of the disease will pose challenges in establishing a treatment regimen which will be efficacious in a large proportion of patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Acceleron, Agios, Celgene/BMS, Keros Therapeutics, Novartis, Taiho, Takeda, Gilead
Research Funding: Agios, AstraZeneca, Celgene/BMS, GSK, Janssen, Novartis
